New Delhi, Oct 14 (IANS) The Indian Council of Medical Research (ICMR) on Monday announced a partnership with domestic pharma giant Zydus Lifesciences to initiate Phase 2 clinical trials of the drug Desidustat in patients with sickle cell disease.
ICMR formalised a Memorandum of Agreement (MoA) with Zydus for a Phase IIa, double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of Desidustat oral tablet against sickle cell disease — a genetic blood disorder characterised by the presence of abnormal haemoglobin (Hb).
This comes after drug regulator DCGI recently granted permission to conduct a Phase IIa trial to evaluate the efficacy and safety of Desidustat.
Desidustat is a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) that stimulates the production of erythropoietin (EPO), a hormone that boosts red blood cell production when oxygen levels are low in the blood.
“This collaboration reflects our commitment to advancing clinical research in India through strategic public-private partnerships. Desidustat was invented in India, and patients with sickle cell disease need therapies in addition to the currently available drug, hydroxyurea,” said Dr. Rajiv Bahl, Secretary, the Department of Health Research and Director General, ICMR.
“Our vision is to ensure that India continues to lead in the development of innovative and affordable healthcare solutions,” he added.
The proportion of patients with Hb response (defined as more than 1 g/dL increase in Hb from baseline) compared to placebo will be measured at week 4 and week 8 as the primary end-point.
The trial will also evaluate key secondary endpoints including mean change in Hb, the proportion of patients requiring blood transfusions, the proportion of patients experiencing a vaso-occlusive crisis, and mean change in percentage of HbSS. HbSS is a severe form, affecting 65 per cent of people who have sickle cell.
“Public-private partnerships in the healthcare sector are essential to deliver novel drugs to achieve the goals of the National Sickle Cell Anaemia Elimination Mission. The initiation of this study reaffirms hope for the 20 million Sickle Cell affected patients in the country for a high potential novel treatment,” said Pankaj Patel, Chairman of Zydus.
Desidustat was discovered at Zydus’ R&D labs and recently approved for the treatment of anaemia in chronic kidney disease patients.
Sickle cell disease is a significant public health concern in India, particularly among certain tribal populations where the prevalence is higher.
According to the National Health Mission (NHM) estimates, there are approximately 20 million sickle cell-affected patients in the country. Every year, 50,000 children with sickle cell anaemia are estimated to be born in India.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
